Submitted for Publication: February 8, 2011; final revision received April 29, 2011; accepted May 1, 2011.
Financial Disclosure: Dr Goldberg reports that he has consulted for Merck and GlaxoSmithKline, receives royalties for use of a cognitive test battery (Brief Assessment of Cognition in Schizophrenia) in clinical trials, and has received an investigator-initiated grant from Eisai/Pfizer. Dr Davies reports that he has received research support from and served as a consultant to Applied Neurosolutions.
Funding/Support: This study was supported by grants from the Litwin-Zucker Alzheimer's Center (Drs Gomar, Conejero-Goldberg, Davies, and Goldberg and Ms Bobes-Bascaran), and by grant FI00322 from Instituto de Salud Carlos III (Dr Gomar).
Additional Information: Data used in the preparation of this article were obtained from the ADNI database (http://adni.loni.ucla.edu/.. As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this article. A complete listing of ADNI investigators is available at http://adni.loni.ucla.edu/. Data collection and sharing for this project was funded by ADNI (grant U01 AG024904 from the National Institutes of Health). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson& Johnson, Eli Lilly and Co, Medpace, Inc, Merck and Co, Inc, Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc, as well as nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory of Neuro Imaging at the University of California, Los Angeles. This research was also supported by grants P30 AG010129 and K01 AG030514 from the National Institutes of Health, and the Dana Foundation.
Additional Contributions: We thank Ted Huey, MD, for commenting on the manuscript.